

**DOCKET NO.:** CELL-0207  
**Application No.:** 10/081,072  
**Office Action Dated:** June 22, 2004

**PATENT**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)

15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Currently amended) A pharmaceutical composition comprising a compound according to claim [1] 32 together with one or more pharmaceutically acceptable carriers, excipients or diluents.
26. (Currently amended) A method for the prophylaxis or treatment of a disease or disorder in a mammal in which the extravasation of leukocytes plays a role, comprising administering to a mammal suffering from such a disease or disorder a therapeutically effective amount of a compound according to claim [1] 32.

27. (Original) A method according to claim 26 wherein said disease or disorder is selected from the group consisting of inflammatory arthritis, multiple sclerosis, allograft rejection, diabetes, inflammatory dermatoses, asthma and inflammatory bowel disease.
28. (Original) A method according to claim 27 wherein said inflammatory arthritis is selected from the group consisting of rheumatoid arthritis, vasculitis and polydermatomyositis.
29. (Original) A method according to claim 27 wherein said inflammatory dermatoses are selected from the group consisting of psoriasis and dermatitis.
30. (Currently amended) A method for inhibiting, in a mammal, the binding of  $\alpha 4$  integrins to the ligands thereof, comprising administering to the mammal an effective amount of a compound according to claim [4] 32.
31. (Original) A method according to claim 30 wherein said  $\alpha 4$  integrins are selected from the group consisting of  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrins.
32. (Newly added) A compound which is ethyl (2*S*)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate.